These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Carbamylated hemoglobin as a therapeutic marker in hemodialysis. Hasuike Y; Nakanishi T; Maeda K; Tanaka T; Inoue T; Takamitsu Y Nephron; 2002 Jun; 91(2):228-34. PubMed ID: 12053058 [TBL] [Abstract][Full Text] [Related]
5. Adequate hemodialysis for patients with terminal uremia. Evolution of concepts and management. Jacobs C Contrib Nephrol; 1989; 71():17-21. PubMed ID: 2680261 [No Abstract] [Full Text] [Related]
6. Skin bleeding time for the evaluation of uremic platelet dysfunction and effect of dialysis. Soyoral YU; Demir C; Begenik H; Esen R; Kucukoglu ME; Aldemir MN; Demirkiran D; Erkoc R Clin Appl Thromb Hemost; 2012; 18(2):185-8. PubMed ID: 22327827 [TBL] [Abstract][Full Text] [Related]
7. Urea monitoring in the dialysis patient. Panzetta G Int J Artif Organs; 1995 Sep; 18(9):530-3. PubMed ID: 8582771 [No Abstract] [Full Text] [Related]
8. Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. Correlations between nerve conduction velocities and altered guanidino compound concentrations. De Deyn PP; Robitaille P; Vanasse M; Qureshi IA; Marescau B Nephron; 1995; 69(4):411-7. PubMed ID: 7777105 [TBL] [Abstract][Full Text] [Related]
9. Comparisons of Kt/V evaluated using an online method and calculated from urea measurements in patients on intermittent hemodialysis. Grzegorzewska AE; Banachowicz W Hemodial Int; 2006 Oct; 10 Suppl 2():S5-9. PubMed ID: 17022752 [TBL] [Abstract][Full Text] [Related]
10. [Control by means of Computer control of the hematochemical picture in chronic uremic patients undergoing periodic hemodialysis treatment]. Novario PG; Pagliano B; Denti E; Segoloni G; Piccoli G; Vercellone A; Coppo R Minerva Nefrol; 1974; 21(5):347-59. PubMed ID: 4467056 [No Abstract] [Full Text] [Related]
11. [The excretion of ascorbic acid and its metabolites in uremia and hemodialysis]. Bakaev VV; Efremov AV Patol Fiziol Eksp Ter; 2000; (2):22-4. PubMed ID: 10846906 [TBL] [Abstract][Full Text] [Related]
12. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. Dirican M; Akca R; Sarandol E; Dilek K J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056 [TBL] [Abstract][Full Text] [Related]
16. Dialysis of the future. Gotch FA Kidney Int Suppl; 1988 Mar; 24():S100-4. PubMed ID: 3163027 [No Abstract] [Full Text] [Related]
17. [Retention of medium sized molecules in uremic serum]. Dall'aglio P; Buzio C; Cambi V; Arisi L; Migone L Proc Eur Dial Transplant Assoc; 1972; 9():409-16. PubMed ID: 4668919 [No Abstract] [Full Text] [Related]
18. Phosphate mass removal during hemodialysis: a comparison between eKT/V-matched conventional and extended dialysis. Sampaio MS; Ruzany F; Dorigo DM; Suassuna JH Am J Nephrol; 2012; 36(2):121-6. PubMed ID: 22776782 [TBL] [Abstract][Full Text] [Related]
19. [pH-independent shifts of the oxygen-dissociation curve before and after hemodialysis]. Weber R; Kleeberg U; Rühle K; Matthys H Schweiz Med Wochenschr; 1971 Dec; 101(49):1795-6. PubMed ID: 5140921 [No Abstract] [Full Text] [Related]
20. [Use of hemodiafiltration in the treatment of patients with uremia]. Burtsev VI; Troĭniakov NK; Rashupkina ZP; Burlinova LP; Karavaeva MG; Kalashnikov SV; Minchenkov AV; Ptitsina SV; Vasina TI Klin Med (Mosk); 1995; 73(4):73-5. PubMed ID: 7474828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]